Institutional members access full text with Ovid®

VALGANCICLOVIR FOR CONGENITAL CMV INFECTION: A PILOT STUDY ON PLASMA CONCENTRATION IN NEWBORNS AND INFANTS

Galli, Luisa MD*; Novelli, Andrea MD†; Chiappini, Elena PhD*; Gervaso, Paola MD*; Cassetta, Maria Iris BS†; Fallani, Stefania BS†; de Martino, Maurizio MD*

Pediatric Infectious Disease Journal: May 2007 - Volume 26 - Issue 5 - pp 451-453
doi: 10.1097/01.inf.0000261111.90075.4d
Brief Reports

The pharmacokinetics of valganciclovir were studied in 8 infants ranging in age from 4 to 90 days (mean 20 days). We suggest that doses of 15 mg/kg given twice daily may be suitable for neonates and young infants.

From the Departments of *Pediatrics and †Pharmacology, University of Florence, Florence, Italy.

Accepted for publication February 7, 2007.

Address for correspondence: Maurizio de Martino, MD, Department of Pediatrics, University of Florence, Florence, Italy. E-mail: maurizio.demartino@unifi.it.

© 2007 Lippincott Williams & Wilkins, Inc.